Financing ·
Celcuity Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $78.9 million, or…
CELCCelcuity Inc.
Celcuity Inc. reported financial results for the quarter ended June 30, 2026, posting a net loss of $78.9 million, or $1.44 per share, compared to a net loss of $45.3 million in the prior year period. The company completed a public offering of convertible senior notes due 2032, generating net proceeds of $557.2 million, which were partially used to prepay $137.0 million in term loan debt. Commercially, Celcuity received FDA approval on July 14, 2026, for REVTORPYK (gedatolisib) to treat HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer and is on track for a commercial launch in late Q3 2026. Additionally, the Phase 3 VIKTORIA-1 trial's PIK3CA mutant cohort achieved its primary endpoint, prompting plans to submit a supplemental New Drug Application in Q3 2026. Celcuity Inc. is a biotechnology company focused on developing and commercializing targeted therapies for solid tumor indications.